About Us

About Us

Who we are

We are the UK’s largest independent laboratory-based contract research organisation (CRO) specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and expert interpretation.

What we do

Through a consultative approach, the XenoGesis team helps to identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns, providing significant time and cost savings for R&D companies. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.

We combine our state-of-the-art in vitro, in vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services. Our laboratory tests demonstrate how the human body might affect the way a drug behaves, backed-up with advice on how to modify the chemical structure of a compound to make it more ‘drug-like.’

By appointing experienced scientists, we are now able to also offer in vitro pharmacology and toxicology services.

Expertise you can count on

Based at BioCity in Nottingham, the core XenoGesis team has an enviable track record of delivery in drug discovery and pre-clinical development.

Company History

Founded in 2011 by Dr Richard Weaver, the company has grown from three to twenty five members of staff in six years. We have increased our lab and office space and continue to invest in the latest cutting-edge technology, ensuring the best possible service for our global client base.

XenoGesis the name

Our company name: XenoGesis is derived from two ancient Greek words, Xenos (ξένος, foreign) and Exegesis (ἐξήγησις, interpretation). Whilst the former part, Xeno refers to xenobiotics, i.e. substances foreign to the body such as drug molecules, the latter exegesis, stands for the critical review and interpretation of data describing the fate of such compounds in the organism.

Find out more

Our services:

Contact the team.